Published • loading... • Updated
Ontario drug funding decision leaves cancer patients disappointed, with few options
Doctors say the province’s funding rules are blocking access to U.S.-approved cancer drugs, forcing patients to pay privately or go without treatment.
- On Wednesday, October 21, 2026, Ontario patient Sabrina Apitz-Grossman was denied provincial coverage for a United States-approved cancer treatment after the Ontario Health Insurance Plan and Case-by-Case Review Program rejected her applications.
- Health Minister Sylvia Jones stated funding strictures protect the Ontario drug approval process and help avoid up to $5.2 billion in additional annual health-care costs.
- Apitz-Grossman noted the treatment costs US$727,000, while nearly half of patients in her situation respond to the therapy; others like Holly Wardlow are paying $78,000 monthly for infusions.
- Critics questioned prioritizing spending over lives, citing Ontario Premier Doug Ford's earlier $29-million private jet purchase, while Apitz-Grossman rejected the idea that saving ICU patients is too expensive.
- Last month, 37-year-old Alex Shved won a court challenge against his OHIP out-of-country denial, but patients like Apitz-Grossman remain without options as funding rules persist.
Insights by Ground AI
21 Articles
21 Articles
Sabrina Apitz-Grossman, 31, denounces the Ontario government's decision to refuse treatment in the United States.
·Montreal, Canada
Read Full Article
Coverage Details
Total News Sources21
Leaning Left16Leaning Right0Center4Last UpdatedBias Distribution80% Left
Bias Distribution
- 80% of the sources lean Left
80% Left
L 80%
C 20%
Factuality
To view factuality data please Upgrade to Premium
